5-Aminosalicylic acid dependency in Crohn's disease: A Danish Crohn Colitis Database study

Sutherland, 2006, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, CD000544 Sutherland, 2006, Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, CD000543 Lochs, 2000, Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI, Gastroenterology, 118, 264, 10.1016/S0016-5085(00)70208-3 McLeod, 1995, Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease, Gastroenterology, 109, 404, 10.1016/0016-5085(95)90327-5 Modigliani, 1996, Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives, Gastroenterology, 110, 688, 10.1053/gast.1996.v110.pm8608877 Prantera, 1999, Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial, Gastroenterology, 116, 521, 10.1016/S0016-5085(99)70172-1 Singleton, 1993, Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group, Gastroenterology, 104, 1293, 10.1016/0016-5085(93)90337-C Sutherland, 1997, A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group, Gastroenterology, 112, 1069, 10.1016/S0016-5085(97)70117-3 Akobeng, 2005, Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease, Cochrane Database Syst Rev, CD003715, 10.1002/14651858.CD003715.pub2 Camma, 1997, Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables, Gastroenterology, 113, 1465, 10.1053/gast.1997.v113.pm9352848 Hanauer, 2004, Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials, Clin Gastroenterol Hepatol, 2, 379, 10.1016/S1542-3565(04)00122-3 Travis, 2006, European evidence based consensus on the diagnosis and management of Crohn's disease: current management, Gut, 55, i16, 10.1136/gut.2005.081950b Loftus, 2004, Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis, Aliment Pharmacol Ther, 19, 179, 10.1111/j.0269-2813.2004.01827.x Van Staa, 2004, 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study, Gastroenterology, 126, 1733, 10.1053/j.gastro.2004.03.016 Munkholm, 1995, Disease activity courses in a regional cohort of Crohn's disease patients, Scand J Gastroenterol, 30, 699, 10.3109/00365529509096316 Silverstein, 1999, Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort, Gastroenterology, 117, 49, 10.1016/S0016-5085(99)70549-4 Duricova, 2009, Infliximab dependency in children with Crohn's disease, Aliment Pharmacol Ther, 29, 792, 10.1111/j.1365-2036.2009.03926.x Munkholm, 1994, Frequency of glucocorticoid resistance and dependency in Crohn's disease, Gut, 35, 360, 10.1136/gut.35.3.360 Wewer, 2006, Infliximab dependency in a national cohort of children with Crohn's disease, J Pediatr Gastroenterol Nutr, 42, 40, 10.1097/01.mpg.0000189137.06151.33 Mahida, 1990, Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease, Digestion, 45, 88, 10.1159/000200228 Rasmussen, 1987, 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa, Scand J Gastroenterol, 22, 877, 10.3109/00365528708991929 Tremaine, 1994, A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis, J Clin Gastroenterol, 19, 278, 10.1097/00004836-199412000-00003 Caspersen, 2008, Infliximab for inflammatory bowel disease in Denmark 1999–2005: clinical outcome and follow-up evaluation of malignancy and mortality, Clin Gastroenterol Hepatol, 6, 1212, 10.1016/j.cgh.2008.05.010 Colombel, 2004, The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients, Gastroenterology, 126, 19, 10.1053/j.gastro.2003.10.047 de Ridder, 2008, Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort, Inflamm Bowel Dis, 14, 353, 10.1002/ibd.20329 Hanauer, 2002, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4 Bebb, 2004, How effective are the usual treatments for Crohn's disease?, Aliment Pharmacol Ther, 20, 151, 10.1111/j.1365-2036.2004.02019.x Robinson, 2001, for the Northwest Gastrointestinal Research Group. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial, Lancet, 358, 976, 10.1016/S0140-6736(01)06105-0 Robinson, 2008, Review article: improving adherence to medication in patients with inflammatory bowel disease, Aliment Pharmacol Ther, 27, 9, 10.1111/j.1365-2036.2008.03604.x Elkjaer, 2010, Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment, Eur J Gastroenterol Hepatol, 22, 695 Bokemeyer, 2009, Predictive factors for a mild course of Crohn's disease, J. Crohn's Colitis, 3, S82, 10.1016/S1873-9946(09)60210-5 Kane, 2001, Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis, Am J Gastroenterol, 96, 2929, 10.1111/j.1572-0241.2001.04683.x Sachar, 1983, Risk factors for postoperative recurrence of Crohn's disease, Gastroenterology, 85, 917, 10.1016/0016-5085(83)90444-4